NMRA

Neumora Therapeutics, Inc.
CAPPED RATING

Neumora Therapeutics, Inc. (NMRA) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (F). The rating has held at D+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
C+
Factor Score 2.5 / 5.0
Growth
C
Factor Score 2.4 / 5.0
Profitability
D-
Factor Score 0.9 / 5.0
Momentum
F
Factor Score 0.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.7
EV / EBITDA -0.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -72.9%
Price Return 12M -84.3%
Catalyst Signal 0.00
Market Cap $81.4M
TTM Revenue N/A
Price / Sales N/A
ROE -187.1%

Historical Factor Score Progression

Held D+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) C (2.4) D- (0.9) F (0.4) C+ (2.6) D+ (1.8)
2026-11-06 C+ (2.5) C (2.3) D- (0.9) F (0.5) C+ (2.7) D+ (1.8)
2026-10-30 C+ (2.5) C (2.2) D- (1.0) F (0.5) C+ (2.7) D+ (1.8)
2026-10-23 C+ (2.5) C (2.2) D- (0.9) F (0.6) C+ (2.6) D+ (1.8)
2026-10-16 C+ (2.5) C (2.2) D- (0.9) F (0.7) C+ (2.6) D+ (1.8)
Page 1 of 4